Lixisenatide
approvedAlso known as: Adlyxin, Lyxumia
**Mechanism of Action** Lixisenatide is a synthetic, short-acting GLP-1 receptor agonist derived from exendin-4, with a half-life of approximately 3 hours. It binds with high affinity to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Its primary distinguishing feature is a pronounced delay in gastric emptying, which reduces postprandial glucose excursions more effectively than longer-acting GLP-1 agonists. This effect is mediated via vagal signaling and central nervous system pathways, leading to reduced food intake and enhanced satiety. **Key Research Findings** Clinical trials (e.g., GetGoal series) demonstrated significant reductions in HbA1c (0.5–1.0%) and fasting/postprandial glucose in type 2 diabetes patients, with a low risk of hypoglycemia. Lixisenatide also showed modest weight loss (1–3 kg) and improved beta-cell function markers. Notably, the ELIXA cardiovascular outcomes trial (n=6,068) confirmed non-inferiority for major adverse cardiac events, with no increased risk of pancreatitis or pancreatic cancer. Gastrointestinal adverse effects (nausea, vomiting) were common but transient, and antibody formation occurred in ~70% of patients without loss of efficacy. **Clinical Relevance** Approved as adjunct to diet/exercise for type 2 diabetes, lixisenatide is particularly suited for patients requiring robust postprandial glucose control. Its short half-life allows flexible dosing (once daily) and rapid offset if adverse effects occur. However, it is contraindicated in gastroparesis and severe renal impairment (eGFR <30 mL/min). Compared to longer-acting GLP-1 agonists, lixisenatide offers a unique profile for targeting post-meal hyperglycemia but requires twice-daily injection in some regimens. For research purposes only — not medical advice.
Key data
C215H347N61O65SResearch & studies
GLP-1 RAs reduced all-cause death (IRR 0.88, NNT=121), CV death (IRR 0.87, NNT=170), and MACE (IRR 0.87, NNT=66).; Serious adverse events, myocardial infarction, acute kidney failure, heart failure, and infections were reduced by 9-15%.; Gastrointestinal disorders increased by 63% and gallbladder disorders by 26%.; No significant differences were observed for stroke, pancreatitis, or neoplasm.
Semaglutide and lixisenatide had significant reporting odds ratios for ocular AEs (1.25 and 1.96, respectively).; Common ocular AEs included blurred vision, visual impairment, and diabetic retinopathy.; Some ocular AEs occurred as early as 10 days after starting GLP-1 RA treatment.; Gene enrichment analysis suggested potential links between GLP-1-related genes and ocular adverse events.
Lixisenatide slowed motor disability progression at 12 months compared to placebo.; After a 2-month washout, off-medication motor scores favored lixisenatide (17.7 vs 20.6).; Gastrointestinal side effects were common: nausea in 46% and vomiting in 13% of the lixisenatide group.; No significant differences were observed in secondary end points between groups.
GLP-1 agonists promote weight loss in both diabetic and non-diabetic patients.; These medications improve hyperglycemia, insulin sensitivity, and blood pressure.; GLP-1 agonists provide cardio-metabolic and renal protection.; The review outlines indications, contraindications, and precautions based on long-term follow-up studies.
Frequently asked questions
What is Lixisenatide?
**Mechanism of Action** Lixisenatide is a synthetic, short-acting GLP-1 receptor agonist derived from exendin-4, with a half-life of approximately 3 hours. It binds with high affinity to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Its primary distinguishing feat
How does Lixisenatide work?
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
What is the research status of Lixisenatide?
Lixisenatide is currently classified as approved, with 719 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Lixisenatide?
Lixisenatide has a molecular weight of approximately 4858 g/mol (formula C215H347N61O65S).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Lixisenatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key